{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:02:04Z","timestamp":1784617324323,"version":"3.55.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Research on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and psychiatric outcomes has expanded rapidly following the clinical success of semaglutide, pharmacoepidemiological signals on psychiatric adverse events, and growing regulatory scrutiny, yet the intellectual structure and thematic evolution of this interdisciplinary field remain uncharacterised. We aimed to map publication trends, conceptual structure, thematic evolution, and collaboration networks of research on GLP-1 RAs and psychiatric outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Bibliographic records were retrieved independently from OpenAlex,\n                      <jats:ext-link>Lens.org<\/jats:ext-link>\n                      , and PubMed (MEDLINE) on 8 April 2026, using parallel Boolean searches restricted to title and abstract fields. After cross-database deduplication and cleaning, 2, 197 documents (1990--2026) were retained. Performance analysis, science mapping (keyword co-occurrence, collaboration networks), and thematic analysis (Callon\u2019s centrality-density map, thematic evolution) were performed using the bibliometrix R package.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The field showed exponential growth, with annual output rising from fewer than 10 publications before 2004 to nearly 500 in 2025. The corpus spanned 1, 063 journals, 9, 269 authors, and 85 countries (h-index 101; mean 21.9 citations\/document). Thematic mapping placed depression in the niche themes quadrant (high density, low centrality), while obesity and diabetes mellitus occupied the basic themes quadrant. Thematic evolution showed depression emerging as a distinct research front only in 2022--2026.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Depression research within the GLP-1 RA literature has developed internal coherence as a niche theme but remains peripheral to the dominant metabolic research front. Bridging this gap through large cardiometabolic trials with psychiatric co-primary endpoints represents a key priority for future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1857078","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:16:41Z","timestamp":1784614601000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 receptor agonists and psychiatric outcomes: a bibliometric analysis of research trends, thematic evolution, and collaboration networks"],"prefix":"10.3389","volume":"17","author":[{"given":"Maria Meritxell","family":"Roca Mora","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n Hospitalarias, Sant Boi de Llobregat","place":["Barcelona, Spain"]},{"name":"Parc Sanitari Sant Joan de D\u00e9u, Sant Boi de Llobregat","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia","family":"Sanchez-Monge","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad Peruana Cayetano Heredia","place":["Lima, Peru"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dibe","family":"Balardini Ayoub","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universidade do Extremo Sul Catarinense","place":["Criciuma, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz P.","family":"Aguiar-Barros","sequence":"additional","affiliation":[{"name":"Department of Medicine, Cesmac University Center","place":["Maceio, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Serrano-Porras","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Universidad Internacional de la Rioja","place":["Logro\u00f1o, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"de Filippis","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, University \u201cMagna Graecia\u201d of Catanzaro","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Schoretsanitis","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neuroscience, Lausanne University Hospital, University of Lausanne","place":["Lausanne, Switzerland"]},{"name":"Psychiatric University Hospital Zurich, Department of Psychiatry, Psychotherapy and Psychosomatics, University of Zurich","place":["Zurich, Switzerland"]},{"name":"Department of Psychiatry, The Zucker Hillside Hospital, Behavioral Health Pavilion, Northwell Health","place":["Glen Oaks, NY, United States"]},{"name":"Department of Psychiatry, Zucker School of Medicine at Northwell\/Hofstra","place":["Hempstead, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/nejmoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2015.07.008","article-title":"Distribution and characterisation of glucagon-like peptide-1 receptor expressing cells in the mouse brain","volume":"4","author":"Cork","year":"2015","journal-title":"Mol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cne.24905","article-title":"A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain","volume":"528","author":"Graham","year":"2020","journal-title":"J Comp Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.70661","article-title":"Efficacy and safety of glucagon-like peptide-1 agonists for psychiatric symptoms: a systematic review","volume":"15","author":"Meshkat","year":"2025","journal-title":"Brain Behav"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbusres.2021.04.070","article-title":"How to conduct a bibliometric analysis: an overview and guidelines","volume":"133","author":"Donthu","year":"2021","journal-title":"J Bus Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.32614\/cran.package.bibliometrix","article-title":"bibliometrix: an R-tool for comprehensive science mapping analysis","volume":"11","author":"Aria","year":"2017","journal-title":"J Informetr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.46510","article-title":"An update on semaglutide research: a bibliometric analysis and a literature review","volume":"15","author":"Dagli","year":"2023","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000002592","article-title":"Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023","volume":"86","author":"Mahapatro","year":"2024","journal-title":"Ann Med Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101194","article-title":"Knowledge domain and emerging trends of glucagon-like peptide 1 receptor agonists in cardiovascular research: a bibliometric analysis","volume":"48","author":"Shou","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2025.100640","article-title":"Global trends and focuses of GLP-1RA in obesity: a bibliometric analysis and visualization from 2014 to 2024","volume":"57","author":"Abdelrahman","year":"2025","journal-title":"Obes Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04574-1","article-title":"Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements","volume":"399","author":"Taha","year":"2026","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B16","volume-title":"R: A Language and Environment for Statistical Computing","year":"2025"},{"key":"B17","article-title":"OpenAlex: a fully-open index of scholarly works, authors, venues, institutions, and concepts","volume-title":"Arxiv:2205.01833","author":"Priem","year":"2022"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-025-05293-3","article-title":"Reference coverage analysis of OpenAlex compared to Web of Science and Scopus","volume":"130","author":"Culbert","year":"2025","journal-title":"Scientometrics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11192-025-05338-7","article-title":"How similar are field-normalized citation impact scores obtained from OpenAlex and three popular commercial databases? An empirical comparison based on large German universities","volume":"130","author":"Scheidsteger","year":"2025","journal-title":"Scientometrics"},{"key":"B20","article-title":"openalexR: getting started with OpenAlex data in R","year":"2026"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11205-020-02281-3","article-title":"Mapping the evolution of social research and data science on 30 years of Social Indicators Research","volume":"149","author":"Aria","year":"2020","journal-title":"Soc Indic Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1300\/j105v01n03_06","article-title":"Sources of information on specific subjects","volume":"137","author":"Bradford","year":"1934","journal-title":"Engineering"},{"key":"B23","article-title":"The frequency distribution of scientific productivity","volume":"16","author":"Lotka","year":"1926","journal-title":"J Wash Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1088\/1742-5468\/2008\/10\/p10008","article-title":"Fast unfolding of communities in large networks","volume":"2008","author":"Blondel","year":"2008","journal-title":"J Stat Mech Theory Exp"},{"key":"B25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/bf02019280","article-title":"Co-word analysis as a tool for describing the network of interactions between basic and technological research: the case of polymer chemistry","volume":"22","author":"Callon","year":"1991","journal-title":"Scientometrics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.048","article-title":"Cognitive dysfunction and metabolic comorbidities in mood disorders: a repurposing opportunity for glucagon-like peptide 1 receptor agonists","volume":"136","author":"Mansur","year":"2018","journal-title":"Neuropharmacology"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review: glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns","year":"2024","journal-title":"Pharmacol Res"},{"key":"B28","unstructured":"EMA Statement on Ongoing Review of GLP-1 Receptor Agonists\n          \n          \n          \n          2023"},{"key":"B29","unstructured":"Meeting Highlights From the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024\n          \n          \n          \n          2024"},{"key":"B30","unstructured":"FDA Requests Removal of Suicidal Behavior and Ideation Warning From Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medicines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S2215-0366(25)00129-4","article-title":"Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator-blinded, randomised controlled trial in Australia","volume":"12","author":"Siskind","year":"2025","journal-title":"Lancet Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(26)00014-3","article-title":"Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study","volume":"13","author":"Taipale","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-2041","article-title":"Semaglutide effects on insulin sensitivity and beta-cell function in patients with schizophrenia, prediabetes, and obesity treated with second-generation antipsychotics: findings from the HISTORI trial","volume":"49","author":"Ganeshalingam","year":"2026","journal-title":"Diabetes Care"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1857078\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:16:43Z","timestamp":1784614603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1857078\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":33,"alternative-id":["10.3389\/fpsyt.2026.1857078"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1857078","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1857078"}}